Company Presentation

AC Bioscience is pioneering ground-breaking therapeutic solutions to potentiate efficacy of immunotherapy (for colorectal cancer) and normalization of tumor vasculature (for pancreatic cancer) where there is a great unmet medical need.
Lead molecule ACB2003.4, a S1P lyase inhibitor, will enter Phase 2a clinical trial for mPAC patients in early 2024 at the Salpêtrière Hospital in Paris. Our second lead molecule, ACB1801, will enter Phase 1 trials for CRC patients in 2025.